Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies

Hematology

Volumn 15, Issue 4, 2010, Pages 240-244

  YaǧcI, Münci ^a   Özkurt, Zübeyde Nur ^a   Yeǧin, Zeynep Arzu ^a   AkI, Zeynep ^a   Sucak, Gülsan Türköz ^a   Haznedar, Rauf ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

chronic lymphocytic leukemia; hematological malignancy; Hepatitis B reactivation; lamivudine; rituximab

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; FAMCICLOVIR; FLUDARABINE; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; LAMIVUDINE; NAVELBINE; NUCLEOSIDE DERIVATIVE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VIRUS DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC LYMPHOCYTIC LYMPHOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE EXACERBATION; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFECTION RISK; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REINFECTION; SIDE EFFECT; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRUS ACTIVATION;

EID: 77955200310     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X12583347114059     Document Type: Article

References (32)

1. Yeo W, Chan PKS, Zong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307
2. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Int Med J 2007; 35: 705-712
3. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712
4. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188
5. Yag?ci M, Acar K, Sucak GT, Aki Z, Bozdayi G, Haznedar R. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBsAg carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608-1612
6. Yeo W, Chan PK, Ho WM et al. Lamivudinee for the prevention of hepatitis B virus resctivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-943
7. Zhong S, Yeo W, Schroder C et al. High hepatitis B virus DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55-59
8. Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudinee in patients with haemato-logical malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603
9. Lau GKK, Leung YH, Fong DY et al. High hepatitis B virus (HBV) viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic stem cell transplantation. Blood 2002; 99: 2324-2330
10. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220
11. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepathology 2003; 37: 1320-1328
12. Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-557
13. Takai S, Tsurumi H, Ando K et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005; 74: 158-165
14. Kim JH, Bang YJ, Park BJ et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 2002; 93: 471-477
15. Kuniyoshi M, Nakamuta M, Sakai H et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. Gastroenterol Hepatol 2001; 16: 215-219
16. Cucuianu A, Patiu M, Duma M et al. Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients. Br J Haematol 1999; 107: 353-356
17. Rossi D, Sala L, Minisini R et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 604-611
18. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24(Suppl. 1): 3-10
19. Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897
20. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611
21. He YF, Li YH, Wang FH et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481-485
22. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudinee therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749
23. Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy-a prospective case series. Am J Hematol 2005; 80: 197-203
24. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudi-nee pophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24: 1003-1016
25. Li YH, He YF, Jiang WQ et al. Lamivudinee prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-1325
26. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamuvidine for chemotherapy-associated hepatitis B reactivation reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009: 94: 998-1005
27. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamuvidine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepatitis 2008; 15: 89-102
28. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62
29. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004; 21: 67-72
30. Ling R, Mutimer D, Ahmed N et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudinee. Hepatology 1996; 24: 711-713
31. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudinee for chronic hepatitis B. Asia hepatitis lamivudinee study group. N Engl J Med 1998; 339: 61-68
32. Chang TT, Lai CL, Chien RN et al. Four years of lamivudinee treatment in Chinese patents with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-1282